Filippo Spriano

1.2k total citations
43 papers, 513 citations indexed

About

Filippo Spriano is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Filippo Spriano has authored 43 papers receiving a total of 513 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 17 papers in Pathology and Forensic Medicine and 17 papers in Oncology. Recurrent topics in Filippo Spriano's work include Lymphoma Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (15 papers) and CAR-T cell therapy research (11 papers). Filippo Spriano is often cited by papers focused on Lymphoma Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (15 papers) and CAR-T cell therapy research (11 papers). Filippo Spriano collaborates with scholars based in Switzerland, Italy and United States. Filippo Spriano's co-authors include Francesco Bertoni, Anastasios Stathis, Chiara Tarantelli, Eugenio Gaudio, Emanuele Zucca, Luciano Cascione, Marilia Barreca, Paola Barraja, Andrea Rinaldi and Alessandra Montalbano and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Cancer Research.

In The Last Decade

Filippo Spriano

42 papers receiving 506 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Filippo Spriano Switzerland	13	320	161	84	76	54	43	513
Sarah T. Diepstraten Australia	10	439 1.4×	159 1.0×	49 0.6×	60 0.8×	43 0.8×	18	651
Mugdha Velankar United States	4	718 2.2×	282 1.8×	45 0.5×	262 3.4×	47 0.9×	7	863
Chandraiah Lagisetti United States	14	574 1.8×	62 0.4×	23 0.3×	72 0.9×	55 1.0×	18	693
Ze-Yan Zhang China	13	444 1.4×	158 1.0×	67 0.8×	22 0.3×	33 0.6×	33	618
Stela Álvarez-Fernández Spain	8	216 0.7×	83 0.5×	16 0.2×	118 1.6×	49 0.9×	11	363
Steve W. Elmore United States	3	369 1.2×	179 1.1×	40 0.5×	29 0.4×	39 0.7×	4	437
Kimberly D. Hill United States	8	263 0.8×	283 1.8×	45 0.5×	31 0.4×	45 0.8×	12	502
Aditi Pandya Martin United States	7	384 1.2×	180 1.1×	37 0.4×	17 0.2×	43 0.8×	8	557
Fen Zhu United States	11	275 0.9×	124 0.8×	103 1.2×	26 0.3×	50 0.9×	17	466
Kamila Wolanin Poland	10	456 1.4×	261 1.6×	19 0.2×	44 0.6×	31 0.6×	13	643

Countries citing papers authored by Filippo Spriano

Since Specialization

Citations

This map shows the geographic impact of Filippo Spriano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Filippo Spriano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Filippo Spriano more than expected).

Fields of papers citing papers by Filippo Spriano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Filippo Spriano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Filippo Spriano. The network helps show where Filippo Spriano may publish in the future.

Co-authorship network of co-authors of Filippo Spriano

This figure shows the co-authorship network connecting the top 25 collaborators of Filippo Spriano. A scholar is included among the top collaborators of Filippo Spriano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Filippo Spriano. Filippo Spriano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fiorentino, Francesco, Filippo Spriano, Valeria Pecci, et al.. (2025). Development of C646‐Based Proteolysis Targeting Chimeras Degraders of the Lysine Acetyltransferases CBP and p300. ChemMedChem. 20(12). e202400792–e202400792. 1 indexed citations

Spriano, Filippo, Chiara Tarantelli, Eugenio Gaudio, et al.. (2024). Targeting CD25 + lymphoma cells with the antibody–drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents. British Journal of Haematology. 205(5). 1873–1882. 2 indexed citations

Zammarchi, Francesca, Karin Havenith, Narinder Janghra, et al.. (2024). ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies. Molecular Cancer Therapeutics. 23(4). 520–531. 6 indexed citations

Sartori, Giulio, Chiara Tarantelli, Filippo Spriano, et al.. (2023). The ATR inhibitor elimusertib exhibits anti‐lymphoma activity and synergizes with the PI3K inhibitor copanlisib. British Journal of Haematology. 204(1). 191–205. 7 indexed citations

Johnson, Zoë, Chiara Tarantelli, Luciano Cascione, et al.. (2023). IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer Research Communications. 3(4). 576–591. 10 indexed citations

Guidetti, Francesca, Alberto J. Arribas, Giulio Sartori, et al.. (2023). Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors. Journal of Clinical Medicine. 12(2). 399–399. 10 indexed citations

Mensah, Afua A., Giulio Sartori, Filippo Spriano, et al.. (2023). Abstract C144: MEN1703/SEL24, a potent PIM inhibitor, demonstrates promising anti-tumour activity in activated B cell like diffuse large B cell lymphoma, mantle cell lymphoma and marginal zone lymphoma cells. Molecular Cancer Therapeutics. 22(12_Supplement). C144–C144. 2 indexed citations

Nalli, Marianna, Ruoli Bai, Eugenio Gaudio, et al.. (2022). RS6077 induces mitotic arrest and selectively activates cell death in human cancer cell lines and in a lymphoma tumor in vivo. European Journal of Medicinal Chemistry. 246. 114997–114997. 7 indexed citations

Mensah, Afua A., Filippo Spriano, Giulio Sartori, et al.. (2021). Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. Blood Advances. 5(10). 2467–2480. 12 indexed citations

10.

Barreca, Marilia, Virginia Spanò, Maria Valeria Raimondi, et al.. (2021). Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity. SHILAP Revista de lepidopterología. 1. 100004–100004. 22 indexed citations

11.

Napoli, Sara, Luciano Cascione, Andrea Rinaldi, et al.. (2021). Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma. Haematologica. 107(5). 1131–1143. 1 indexed citations

12.

Spriano, Filippo, Anastasios Stathis, & Francesco Bertoni. (2020). Targeting BET bromodomain proteins in cancer: The example of lymphomas. Pharmacology & Therapeutics. 215. 107631–107631. 54 indexed citations

13.

Lupi, Monica, Rosaria Chilà, Chiara Tarantelli, et al.. (2019). DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas. Molecular Cancer Therapeutics. 18(7). 1255–1264. 29 indexed citations

14.

Hicks, Stuart W., Chiara Tarantelli, Eugenio Gaudio, et al.. (2019). The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Haematologica. 104(8). 1633–1639. 18 indexed citations

15.

Fallacara, Anna Lucia, Mattia Mori, Francesca Musumeci, et al.. (2019). Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines. European Journal of Medicinal Chemistry. 181. 111545–111545. 14 indexed citations

16.

Tarantelli, Chiara, Lu Zhang, Eugenio Gaudio, et al.. (2019). The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents. Haematologica. 104(7). e307–e309. 13 indexed citations

17.

Spriano, Filippo, Chiara Tarantelli, Gaetanina Golino, et al.. (2019). THE ANTI‐CD25 ANTIBODY‐DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT‐301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES. Hematological Oncology. 37(S2). 323–324. 6 indexed citations

18.

Tarantelli, Chiara, Elena Bernasconi, Eugenio Gaudio, et al.. (2018). BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. ESMO Open. 3(6). e000387–e000387. 21 indexed citations

19.

Cascione, Luciano, Eugenio Gaudio, Chiara Tarantelli, et al.. (2018). Abstract 4275: Analysis of gene and protein expression in lymphoma cell lines using multiple platforms. Cancer Research. 78(13_Supplement). 4275–4275. 1 indexed citations

20.

Gaudio, Eugenio, Ivo Kwee, Filippo Spriano, et al.. (2017). Abstract 154: The phosphatidylinositol-3-kinase (PI3K) inhibitor (i) copanlisib is active in preclinical models of B-cell lymphomas as single agent and in combination with conventional and targeted agents including venetoclax and palbociclib. Cancer Research. 77(13_Supplement). 154–154. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact